الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 115 |  |  |
| | | from | 115 | | |
المستخلص
SUMMARY
Stroke is a very common neurological disease. It was the second most frequent cause of mortality worldwide in 1990.
Genetics has revolutionized neurological research. Many individuals with a high risk of developing stroke can be identified by genetic testing. It may lead to successful early prevention or delay the onset of the disease by aggressive treatment of known risk factors.
This study based on Case-Control assessment of Plasminogen Activator Inhibitor -1 -675 (4G/5G) polymorphism in ischemic stroke patients.
Subjects were divided into two groups; Group I; 46 adults patients fulfilling the following criteria: (1) acute onset of clinical symptoms suggestive of stroke, (2) the ischemic stroke is the first attack. (3) no hemorrhage on CT scan of the brain. Patients were excluded when (1) they are older than 70 years, (2) they have previous attack of hemorrhagic stroke, or myocardial infarction, (3) they had history of cancer, (4) they had history of chronic diseases and (5) their relatives refused to participate in the study; and Group II; Normal control individuals fulfilling the following criteria: (1) They match the same sex of the first group, (2) - they matched the same age (+/- one year) of the first group, and (3) they had no history of chronic disease. Individuals were excluded when (1) they were older than 70 years, (2) they had previous attack of ischemic stroke, hemorrhagic stroke, or myocardial infarction, (3) they had history of cancer, (4) they had history of chronic diseases and (5) they refused to participate in the study.
The data fulfilled about patients including medical history, clinical examination, & chemical analysis of fasting blood glucose, lipids profile, and Real-Time PCR for genomic DNA study.
The present study assessed the relation between PAI-1 -675 (4G/5G) polymorphism and the risk of stroke, our findings oppose the majority of studies that reported an association between PAI-1 -675 (4G/5G) polymorphism and ischemic stroke. It is found in the present study that the (4G/4G) genotype to confer increased risk of stroke, not the (4G/5G) or (5G/5G) genotype as previously reported. The findings may be limited to this study population, but this is not obviously the case.
SUMMARY
Stroke is a very common neurological disease. It was the second most frequent cause of mortality worldwide in 1990.
Genetics has revolutionized neurological research. Many individuals with a high risk of developing stroke can be identified by genetic testing. It may lead to successful early prevention or delay the onset of the disease by aggressive treatment of known risk factors.
This study based on Case-Control assessment of Plasminogen Activator Inhibitor -1 -675 (4G/5G) polymorphism in ischemic stroke patients.
Subjects were divided into two groups; Group I; 46 adults patients fulfilling the following criteria: (1) acute onset of clinical symptoms suggestive of stroke, (2) the ischemic stroke is the first attack. (3) no hemorrhage on CT scan of the brain. Patients were excluded when (1) they are older than 70 years, (2) they have previous attack of hemorrhagic stroke, or myocardial infarction, (3) they had history of cancer, (4) they had history of chronic diseases and (5) their relatives refused to participate in the study; and Group II; Normal control individuals fulfilling the following criteria: (1) They match the same sex of the first group, (2) - they matched the same age (+/- one year) of the first group, and (3) they had no history of chronic disease. Individuals were excluded when (1) they were older than 70 years, (2) they had previous attack of ischemic stroke, hemorrhagic stroke, or myocardial infarction, (3) they had history of cancer, (4) they had history of chronic diseases and (5) they refused to participate in the study.
The data fulfilled about patients including medical history, clinical examination, & chemical analysis of fasting blood glucose, lipids profile, and Real-Time PCR for genomic DNA study.
The present study assessed the relation between PAI-1 -675 (4G/5G) polymorphism and the risk of stroke, our findings oppose the majority of studies that reported an association between PAI-1 -675 (4G/5G) polymorphism and ischemic stroke. It is found in the present study that the (4G/4G) genotype to confer increased risk of stroke, not the (4G/5G) or (5G/5G) genotype as previously reported. The findings may be limited to this study population, but this is not obviously the case.